Safety report of a randomized phase II trial to evaluate the combination of cetuximab plus accelerated concomitant boost radiotherapy (RT) followed or not followed by cetuximab monotherapy in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx

Mesı́a, Ricard; Rueda, A.; Vera, Ruth; Lozano, A.; Medina, J. A.; Bujanda, David Aguiar; Vega, F. Arias de la; Triana, Gustavo; Carles, Joan; López, Ricardo Calvo

doi:10.1200/jco.2008.26.15_suppl.6076

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we evaluated maintenance anti-EGFR therapy, specifically cetuximab treatment, in reducing recurrences after radiotherapy in a preclinical setting. At present, this topic has important implications in patient management, and several preclinical studies and clinical trials have been undertaken to elucidate answers to this question [9,18]. The main accomplishment of our study was to demonstrate the feasibility of using an EGFR antibody to inhibit the progression of a subpopulation of A431 cells that survived a biologically significant dose of radiation, as likely occurs in residual disease.…”

Section: Discussionmentioning

confidence: 97%

Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy

et al. 2010

View full text Add to dashboard Cite

Background. The benefits of radiotherapy and cetuximab have encouraged evaluation of cetuximab after radiotherapy. The aims of this study were to preclinically evaluate the efficacy of cetuximab maintenance after radiotherapy and eventually determine its mechanisms of action.Methods. The A431 human carcinoma cell line was treated in culture with fractionated radiotherapy and cetuximab. The surviving cells were injected s.c. into nude mice to mimic microscopic residual disease. The animals were randomized to receive either cetuximab or saline solution. Tumor growth, cell proliferation (Ki-67), microvessel density (MVD), epidermal growth factor receptor (EGFR) and transforming growth factor (TGF-␣) mRNA transcription, and vascular endothelial growth factor (VEGF) secretion were measured.

show abstract

Section: Discussionmentioning

confidence: 97%

Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy

et al. 2010

View full text Add to dashboard Cite

show abstract

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy

Chan

Glenny

Weldon

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer

Fujisawa

2014

Int J Clin Oncol

View full text Add to dashboard Cite

The multidisciplinary approach is becoming the standard for treatment of advanced head and neck cancer. Combined modality treatment preserves quality of life as well as improving the length of survival time. Molecular targeted drugs have become very important in the multidisciplinary approach for the treatment of advanced head and neck cancer. Cetuximab has been shown to have locoregional control and additional survival benefits in locally advanced squamous cell carcinoma of the head and neck as well as additional survival benefits in distant metastatic/recurrent squamous cell carcinoma of the head and neck. Recently, many clinical studies of the multidisciplinary approach including cetuximab have been carried out in Europe and the US. It has been shown that cetuximab in combination with radiotherapy (RT) is significantly superior to the RT alone in median locoregional control duration and median overall survival (OS). For recurrent or metastatic disease, the results of a phase III randomized control study of CDDP + 5-fluorouracil combination therapy with or without cetuximab reported that OS was significantly longer with than without cetuximab, demonstrating an additional survival benefit of cetuximab. Many trials including induction chemotherapy are being conducted. Clinical trials with cetuximab have also been conducted in Japan. Though combination with cetuximab shows some benefit, further studies are necessary to obtain the standard treatments for a multidisciplinary approach for advanced head and neck cancer.

show abstract

Safety report of a randomized phase II trial to evaluate the combination of cetuximab plus accelerated concomitant boost radiotherapy (RT) followed or not followed by cetuximab monotherapy in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx

Cited by 5 publications

References 0 publications

Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy

Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy

Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer

Contact Info

Product

Resources

About